Aspergillosis Pipeline: 20+ Promising Therapies Poised to Redefine the Aspergillosis Treatment Landscape | DelveInsight

The treatment paradigm for Aspergillosis, a serious fungal infection primarily affecting immunocompromised individuals, is rapidly evolving with a robust pipeline of antifungal agents under clinical and preclinical development. Leading pharmaceutical and biotech companies such as Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, and TFF Pharmaceuticals are at the forefront, developing next-generation therapies aimed at overcoming resistance issues and improving patient outcomes through novel mechanisms of action and targeted delivery systems.

DelveInsight's "Aspergillosis - Pipeline Insight, 2025" offers an in-depth analysis of the ongoing research and development efforts in this space, capturing critical insights into investigational drugs across all phases of clinical development. The report provides comprehensive profiles of pipeline candidates, including their mechanisms of action, clinical trial statuses, regulatory milestones, and projected timelines for market entry.

This pipeline intelligence report also explores emerging trends in Aspergillosis treatment based on molecule type, mode of administration (including inhaled therapies), and therapeutic targets. Furthermore, it highlights key unmet needs, evolving regulatory frameworks, strategic collaborations, and the potential of pipeline therapies to disrupt the current treatment landscape and improve antifungal stewardship globally.

Interested in learning more about the current treatment landscape and the key drivers shaping the aspergillosis pipeline? Click here: https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Aspergillosis Pipeline Report
• DelveInsight's aspergillosis pipeline analysis depicts a strong space with 20+ active players working to develop 20+ pipeline drugs for aspergillosis treatment.
• The leading aspergillosis companies include Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others are evaluating their lead assets to improve the aspergillosis treatment landscape.
• Key aspergillosis pipeline therapies in various stages of development include RT001, Omaveloxolone, Vatiquinone, MIB-626, DT-216, CTI-1601, MIN-102, EryDex, BIIB132, MBM-01, IB1001, Troriluzole, Elamipretide, GTX-102, SLS-005, KPS-0373, VO 659, LX2006, AVB-202, STRX 110, Stemchymal, S-0373, Allo BM-MSC, and others.
• In September 2024, F2G secured $100 million in funding to advance olorofim, an investigational antifungal for invasive aspergillosis. The Phase III OASIS trial is ongoing, with results expected by September 2025.
• In March 2024, following the FDA approval for the antifungal therapy in December 2023, Astellas' CRESEMBA (isavuconazonium sulfate) gained FDA orphan drug exclusivity and pediatric market exclusivity for the treatment of invasive aspergillosis (IA) and invasive mucormycosis (IM).
• In Feb 2024, Matinas BioPharma announced an agreement with the FDA to conduct a single Phase III trial for MAT2203, an oral therapy for invasive aspergillosis. The global study, ORALTO, is set to begin enrollment in the second half of 2024, spanning approximately 24 months across 65 sites worldwide.
• In December 2023, Astellas Pharma US, Inc. announced that the FDA approved CRESEMBA® (isavuconazonium sulfate) for treating invasive aspergillosis (IA) and invasive mucormycosis (IM) in pediatric patients. CRESEMBA for injection is approved for children aged 1 year and older, while the capsule formulation is approved for those aged 6 years and older weighing 16 kg or more. This makes CRESEMBA the only azole antifungal approved for IA and IM in pediatric patients as young as one.

Request a sample and discover the recent breakthroughs happening in the aspergillosis pipeline landscape @ https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Aspergillosis Overview
Aspergillosis is an infection caused by Aspergillus, a common mold that thrives both indoors and outdoors. When inhaled, the spores of Aspergillus can enter the body, potentially leading to an infection. Individuals with compromised immune systems or pre-existing lung conditions are particularly vulnerable to the harmful effects of Aspergillus. There are several types of Aspergillosis, including Allergic Bronchopulmonary Aspergillosis (ABPA), Allergic Aspergillus Sinusitis, Azole-Resistant Aspergillus fumigatus, Aspergilloma, Chronic Pulmonary Aspergillosis, Invasive Aspergillosis, and Cutaneous Aspergillosis. Diagnosis typically involves a detailed patient history, along with various tests such as blood tests to detect antibodies, allergens, or fungal molecules; imaging tests like X-rays or CT scans; and sputum culture or stain analysis to examine mucus from the airways. Treatment for Aspergillosis often includes oral corticosteroids, antifungal medications, and, in some cases, surgery.

Find out more about aspergillosis medication @ https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Aspergillosis Treatment Analysis: Drug Profile
PC945: Pulmocide
PC945 is a potent, long-acting antifungal triazole that demonstrates efficacy against a wide range of both azole-susceptible and azole-resistant Aspergillus fumigatus strains. It is being developed as an inhaled treatment for pulmonary aspergillosis, designed to deliver high local concentrations in the lungs, with prolonged retention in lung tissues and minimal systemic exposure for a long duration of action.

Dupilumab: Regeneron/Sanofi
Dupilumab (Dupixent) is an interleukin-4 (IL-4) receptor alpha antagonist, a human monoclonal antibody of the immunoglobulin G4 subclass. It works by inhibiting IL-4 and IL-13 signaling through binding to the IL-4 receptor alpha subunit. Dupilumab is currently undergoing Phase III clinical trials to assess its effectiveness in treating patients with Allergic Bronchopulmonary Aspergillosis.

Learn more about the novel and emerging aspergillosis pipeline therapies @ https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Aspergillosis Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

By Molecule Type
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy

Scope of the Aspergillosis Pipeline Report
• Coverage: Global
• Key Aspergillosis Companies: Regeneron/Sanofi, Pulmocide, Astellas Pharma, Cipla/Pulmatrix, F2G, Cellix Bio, SCYNEXIS, TFF Pharmaceuticals, Matinas BioPharma, Amplyx Pharmaceuticals, Cidara Therapeutics, ImmuPharma, Takis, and others.
• Key Aspergillosis Pipeline Therapies: RT001, Omaveloxolone, Vatiquinone, MIB-626, DT-216, CTI-1601, MIN-102, EryDex, BIIB132, MBM-01, IB1001, Troriluzole, Elamipretide, GTX-102, SLS-005, KPS-0373, VO 659, LX2006, AVB-202, STRX 110, Stemchymal, S-0373, Allo BM-MSC, and others.

Dive deep into rich insights for drugs used for aspergillosis treatment; visit @ https://www.delveinsight.com/report-store/aspergillosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Aspergillosis Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Aspergillosis Pipeline Therapeutics
6. Aspergillosis Pipeline: Late-Stage Products (Phase III)
7. Aspergillosis Pipeline: Mid-Stage Products (Phase II)
8. Aspergillosis Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.